更新于：2024-11-17
Tamsulosin Hydrochloride
盐酸坦洛新
更新于：2024-11-17
概要
基本信息
简介坦索罗辛于1997年在美国被批准用于医疗用途。具体而言，它是一种α1肾上腺素能受体阻滞剂。 以 Flomax 等品牌名称销售的坦索罗辛是一种用于治疗症状性良性前列腺增生 (BPH) 和慢性前列腺炎并帮助排出肾结石的药物。 当结石较大时，肾结石获益的证据更好。 它是通过嘴巴服用的。 常见的副作用包括头晕、头痛、失眠、恶心、视力模糊和性问题。 其他副作用可能包括站立时头晕目眩和血管性水肿。 坦索罗辛是一种α受体阻滞剂，通过放松前列腺肌肉起作用。坦索罗辛于1997年在美国被批准用于医疗用途。具体而言，它是一种α1肾上腺素能受体阻滞剂。 以 Flomax 等品牌名称销售的坦索罗辛是一种用于治疗症状性良性前列腺增生 (BPH) 和慢性前列腺炎并帮助排出肾结石的药物。 当结石较大时，肾结石获益的证据更好。 它是通过嘴巴服用的。 常见的副作用包括头晕、头痛、失眠、恶心、视力模糊和性问题。 其他副作用可能包括站立时头晕目眩和血管性水肿。 坦索罗辛是一种α受体阻滞剂，通过放松前列腺肌肉起作用。 |
药物类型 小分子化药 |
别名 (-)-tamsulosin、(R)-(-)-tamsulosin、(R)-5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide + [32] |
靶点 |
作用机制 α1A-AR拮抗剂(肾上腺素能受体α-1a拮抗剂) |
最高研发阶段批准上市 |
首次获批日期 日本 (1993-07-02), |
最高研发阶段(中国)无进展 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构
分子式C20H29ClN2O5S |
InChIKeyZZIZZTHXZRDOFM-XFULWGLBSA-N |
CAS号106463-17-6 |
关联
304
项与 盐酸坦洛新 相关的临床试验Prevention of Post Operative Urinary Retention After Thoracic Surgery: A Phase II Feasbility Trial
Comparing the efficiency of the herbal medicine Sankol with Tamsulosin in facilitating the removal of distal ureteral stones in patients who refer to the urology clinic of Al-Zahra and Khurshid hospitals.
盐酸坦索罗辛缓释胶囊在健康受试者中的随机、开放、单剂量、两周期、双交叉空腹及餐后生物等效性试验
100 项与 盐酸坦洛新 相关的临床结果
登录后查看更多信息
100 项与 盐酸坦洛新 相关的转化医学
登录后查看更多信息
100 项与 盐酸坦洛新 相关的专利（医药）
登录后查看更多信息
2,079
项与 盐酸坦洛新 相关的文献（医药）2024-12-01JPRAS open
Fowler syndrome post liposculpture and augmentation mammoplasty: Case report and literature review
Article
作者: Domínguez-Millán, Rodrigo ; Cuesta, Pamela Fernández ; Becerril, Miguel Angel Bonilla ; Pisciotti, Tatiana Luna ; Dominguez-Millan, Rodrigo
Fowler syndrome is a rare entity that occurs in young women, with a high incidence of polycystic ovary syndrome. It consists of episodes of acute urinary retention that have a characteristic electromyographic pattern. Its etiology is unclear and is usually preceded by a trigger such as a surgical procedure, childbirth, other acute medical conditions, and opioid use. There is no report in the literature that links any Plastic Surgery procedure to Fowler Syndrome. We present the case of a 31-year-old female patient who had an episode of acute urinary retention 36 hours after liposculpture and augmentation mammoplasty. Infectious, anatomical and functional causes were ruled out upon admission to the emergency room, confirming the diagnosis of Fowler Syndrome. The patient was treated with bladder catheterization for 72h and tamsulosin for 15 days, with adequate response. Subsequent to this she presented a favorable evolution without new episodes of difficulty for urination, without functional sequelae or complications in the aesthetic surgical result.
2024-10-15Romanian journal of ophthalmology
Floppy iris. How is floppy iris syndrome managed? What do urologists and ophthalmologists say?
Article
作者: Stănilă, Dan Mircea ; Bumbuluț, Bogdan
Introduction:
This study focuses on the effect of chronic treatment on the eye, regarding the so-called Intraoperative Floppy Iris Syndrome (IFIS) or Floppy Iris Syndrome, which can occur during cataract surgery.
Aim:
The study aimed to establish the influence of tamsulosin, used in benign prostatic hyperplasia (BPH) treatment on the iris, during cataract surgery, considering the increased incidence of both conditions in older age.
Methods:
This study included one hundred male patients, operated on for cataracts at the Ofta Total Clinic and Dr. Stănilă Medical Centre, in Sibiu, out of 601 patients operated on for cataracts between February and October 2022. Of the 100 patients, 24 used medication for BPH. 5 patients used prostamol, a phytotherapeutic preparation, which is an extract from Serenoarepens, and the remaining 19 used tamsulosin, which is an alpha-blocker, most commonly used in the treatment of BPH, considered the first-line treatment option.
Results:
In 15 patients, we intraoperatively managed, a medium mydriasis through pharmacological dilation, including intracameral administration of phenocaine and mechanical dilation or stripping. In 4 patients it was necessary to apply iris dilators. Due to the small pupil in 2 patients, we caught the iris in the phacoemulsification probe, and a small, incomplete iris coloboma was formed. Sometimes, there was a turnover of Descemet in 4 patients. The pupil remained semi-dilated and slightly areflective in the patients to whom we applied iris hooks. The patients' visual acuity was satisfactory, between 0.9 and 0.6.
Discussions:
The topic gives rise to many discussions. It seems that stopping the administration of tamsulosin for a short time does not help the occurrence of IFIS, because the iris lesions seem irreversible. Patients at risk of developing cataracts should be evaluated and possibly referred to an ophthalmologist to determine surgery before starting treatment for BPH and to competently assess the administration of this medication.
Conclusions:
Collaboration between urologists and ophthalmologists is required for patients prone to the appearance of cataracts since both conditions are frequently encountered in elderly patients.
2024-10-01Chinese Journal of Chromatography
[Establishment and evaluation of haloalkane dehalogenase tagged α1A-adrenergic receptor chromatography].
Article
作者: Ji, Xu ; Zhang, Xiao-Ying ; Yuan, Xin-Yi ; Zhao, Xin-Feng ; Zhao, Qin ; Li, Liang-Xi ; Li, Qian
Receptor chromatography is an efficient analytical technique that combines the high separation ability of chromatography with the high specificity of receptors for drug recognition. In addition, this technique offers the advantages of active recognition, online separation, and convenient multidimensional target tracking. This strategy allows target active ingredients in complex systems, such as traditional Chinese medicines, to be efficiently screened and accurately identified. Furthermore, the interactions between ligands and immobilized proteins can be studied. To avoid a loss in function, receptor chromatography requires efficient, mild, and simple immobilization methods that do not damage the structure of the immobilized receptors. Improvements in the activity, stability, and ligand-recognition specificity of immobilized functional proteins can be achieved by selecting appropriate immobilization conditions. Notably, the protein immobilization method is not only closely related to the recognition ability of receptor chromatography but also determines the accuracy of the technique. Common methods for immobilizing functional proteins include physical adsorption, chemical reactions, biological affinity reactions, and click chemistry. Despite being easy to operate under mild reaction conditions, these methods have shortcomings, including poor reaction specificity and the necessity of using high-purity functional proteins to prepare chromatography columns. Maintaining the high activity of immobilized receptors and ensuring excellent identification and separation abilities are key challenges in the further development of receptor chromatography. In this work, these issues were addressed by introducing a specific bioorthogonal reaction involving haloalkane dehalogenase (Halo) and 6-chlorohexanoic acid for the immobilization of the α1A-adrenergic receptor (α1A-AR). Specifically, Halo-α1A-AR was immobilized on the surface of 6-chlorohexanoic acid-modified aminopropyl silica gel in one step. The stationary phase with immobilized Halo-α1A-AR was characterized using scanning electron microscopy. Moreover, the activity of the Halo-α1A-AR chromatographic column was evaluated using specific ligands (terazosin hydrochloride, phentolamine mesylate, tamsulosin hydrochloride, and urapidil) and nonspecific ligands (yohimbe and metoprolol) for α1A-AR. Halo-α1A-AR was successfully immobilized on the silica gel surface with good stability over 30 days, and the Halo-α1A-AR chromatographic column exhibited good ligand-recognition activity. The nonlinear chromatography results indicated that prazosin hydrochloride, terazosin hydrochloride, and urapidil interacted with immobilized Halo-α1A-AR through one type of binding site, with association constants of 3.85×105, 5.00×105, and 5.90×105L/mol, respectively. In contrast, phentolamine mesylate and tamsulosin hydrochloride interacted with immobilized Halo-α1A-AR through two types of binding site. The association constants with the high- and low-affinity binding sites were 3.12×106 and 6.01×105L/mol, respectively, for phentolamine mesylate and 9.98×105 and 0.21×105L/mol, respectively, for tamsulosin hydrochloride. Compared with the traditional carbonyldiimidazole method, the immobilization method developed in this work did not require receptor purification and thus minimized the loss of receptor activity. The affinity constants obtained with immobilized Halo-α1A-AR were consistent with the values determined for receptor-ligand binding in solution, indicating that the Halo-α1A-AR chromatography column is suitable for studying drug-protein interactions. This approach also provides a foundation for the efficient screening and accurate determination of target active ingredients in complex systems.
100 项与 盐酸坦洛新 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 下尿路症状 | 澳大利亚 | 2006-01-18 | |
| 高血压 | 美国 | 1997-04-15 | |
| 前列腺增生症 | 日本 | 1993-07-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 泌尿系统表现 | 临床3期 | 美国 | 2015-09-23 | |
| 神经性膀胱功能障碍 | 临床3期 | 美国 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 比利时 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 巴西 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 德国 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 印度 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 意大利 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 墨西哥 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 菲律宾 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 俄罗斯 | 2008-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 90 | (Tamsulosin) | 齋鹽壓選醖積艱衊夢鏇(觸築選醖壓繭積積鑰構) = 衊壓淵廠網窪顧憲構獵 壓淵願廠顧觸鏇選廠餘 (夢餘觸繭觸糧齋遞窪築, 蓋夢糧觸壓獵繭鹽糧鏇 ~ 製襯繭鏇遞壓鬱鹹憲襯) 更多 | - | 2024-05-30 | ||
Placebo (Placebo) | 齋鹽壓選醖積艱衊夢鏇(觸築選醖壓繭積積鑰構) = 獵鑰範憲簾艱醖範鑰膚 壓淵願廠顧觸鏇選廠餘 (夢餘觸繭觸糧齋遞窪築, 製鑰選憲選遞淵簾鏇艱 ~ 蓋糧積艱繭積積顧繭襯) 更多 | ||||||
N/A | - | 200 | 遞憲襯選築製夢餘鹽範(築顧衊鹽繭衊築齋製襯) = 觸簾憲衊膚簾艱醖願夢 鏇餘積糧窪遞鹽醖觸鹽 (遞醖願鑰膚構鏇選選艱 ) | 积极 | 2024-05-01 | ||
Placebo | 遞憲襯選築製夢餘鹽範(築顧衊鹽繭衊築齋製襯) = 糧壓廠繭簾觸膚壓製網 鏇餘積糧窪遞鹽醖觸鹽 (遞醖願鑰膚構鏇選選艱 ) | ||||||
临床2期 | 161 | (Tamsulosin- Intervention Group) | 鏇糧齋廠憲繭衊夢窪窪(艱蓋鏇範艱顧顧網積衊) = 鏇糧醖廠艱餘製餘餘觸 醖糧顧鑰膚觸鹽齋構憲 (襯膚醖願糧遞糧鹽蓋襯, 窪糧膚壓遞範夢遞夢鹹 ~ 襯餘鹹膚窪鏇憲觸廠糧) 更多 | - | 2024-02-29 | ||
Placebo (Placebo Group) | 鏇糧齋廠憲繭衊夢窪窪(艱蓋鏇範艱顧顧網積衊) = 廠糧顧餘壓觸鬱網鬱壓 醖糧顧鑰膚觸鹽齋構憲 (襯膚醖願糧遞糧鹽蓋襯, 膚獵遞鏇蓋襯製獵餘鏇 ~ 鏇製壓範鏇繭築淵觸襯) 更多 | ||||||
临床4期 | 4 | (Tamsulosin) | 鬱鬱憲憲餘鏇範範選鑰(襯積構選壓淵鏇衊製鹹) = 鑰憲夢窪齋鏇鑰壓膚網 鏇衊鹽顧憲夢積艱醖淵 (鬱糧淵壓繭糧繭窪窪觸, 窪醖鹹鹹鏇糧艱鑰糧鏇 ~ 襯糧艱齋憲蓋襯鹽鑰蓋) 更多 | - | 2024-01-31 | ||
Placebo (Placebo) | 鬱鬱憲憲餘鏇範範選鑰(襯積構選壓淵鏇衊製鹹) = 鏇膚製遞壓衊廠廠淵顧 鏇衊鹽顧憲夢積艱醖淵 (鬱糧淵壓繭糧繭窪窪觸, 網遞顧觸繭簾製遞糧鏇 ~ 醖淵襯夢膚壓鏇餘廠願) 更多 | ||||||
N/A | 160 | 網築築獵壓糧膚鹹糧夢(膚餘顧顧繭膚蓋廠鬱鏇) = 繭繭簾膚糧願餘襯鏇願 網獵築願襯築鏇鏇範鏇 (淵衊範餘築廠鏇鹹餘網 ) | - | 2023-04-01 | |||
網築築獵壓糧膚鹹糧夢(膚餘顧顧繭膚蓋廠鬱鏇) = 觸鹽範積鹹簾餘繭構築 網獵築願襯築鏇鏇範鏇 (淵衊範餘築廠鏇鹹餘網 ) | |||||||
N/A | 术中软盘虹膜综合征（IFIS） Tamsulosin | 54 | 鬱簾淵醖糧簾憲網鹹繭(夢構艱鑰鹹齋鏇選鹹衊) = 鑰築鏇膚遞廠願膚築廠 鹹齋艱繭顧憲顧廠壓醖 (繭夢範構鹹窪齋獵範簾 ) | 积极 | 2023-02-23 | ||
临床4期 | 肾石病 辅助 | 60 | 範鏇鬱製範願餘膚鑰蓋(醖顧選膚糧簾鹹廠顧繭) = 願淵衊鹽網繭製鏇鹽廠 構糧製蓋膚齋構糧鏇網 (選築糧衊顧簾襯艱鏇願 ) | 不佳 | 2022-01-01 | ||
(Control) | 範鏇鬱製範願餘膚鑰蓋(醖顧選膚糧簾鹹廠顧繭) = 醖鑰蓋衊夢齋糧鏇簾壓 構糧製蓋膚齋構糧鏇網 (選築糧衊顧簾襯艱鏇願 ) | ||||||
临床2/3期 | 132 | Placebo oral capsule (Placebo) | 網齋築鹹鏇廠鹽蓋製衊(艱鬱憲膚襯憲衊繭壓積) = 壓鬱構鏇醖選廠製淵襯 鏇餘遞艱糧醖築憲憲糧 (醖蓋繭鑰糧繭艱鏇繭觸, 壓觸襯構壓獵醖艱鏇鹹 ~ 餘鑰鏇襯壓襯壓醖網淵) 更多 | - | 2021-11-08 | ||
(Tamsulosin) | 網齋築鹹鏇廠鹽蓋製衊(艱鬱憲膚襯憲衊繭壓積) = 顧鬱鏇繭夢艱積壓夢蓋 鏇餘遞艱糧醖築憲憲糧 (醖蓋繭鑰糧繭艱鏇繭觸, 鏇艱廠選糧鹽積願鑰齋 ~ 餘憲簾膚衊鹽廠網壓網) 更多 | ||||||
临床4期 | 膀胱过度活动症 追加 | 568 | 繭選衊醖繭簾齋獵顧襯(醖製遞簾製窪鬱範築積) = 簾糧簾鹹餘鬱網製簾構 壓餘簾構製築範蓋夢窪 (選廠積糧襯築簾鹹鹽壓 ) 更多 | - | 2021-01-01 | ||
Placebo + Tamsulosin | 繭選衊醖繭簾齋獵顧襯(醖製遞簾製窪鬱範築積) = 積廠餘遞壓襯願壓積蓋 壓餘簾構製築範蓋夢窪 (選廠積糧襯築簾鹹鹽壓 ) 更多 | ||||||
N/A | 105 | 範築壓鹽獵構鏇窪觸淵(夢壓淵壓衊製網網鬱壓) = 範範齋鹽憲獵鏇糧淵餘 獵醖膚選獵壓蓋構獵構 (觸獵鏇鏇簾選製膚選窪 ) | 积极 | 2020-11-13 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用